Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-HAE phase 3 study of ADX-324 for hereditary angioedema
CTR20261309Phase 3Active
- Sponsor
- YuanYi Biotech
- Start
- Jun 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of onvuzosiran in hereditary angioedema (HAE), sponsored by YuanYi Biotech. Started Jun 2026; status: active.
02
Drugs
onvuzosiran
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on CTR20261309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261309.